When pricing a new biologic drug, developers consider medical value, direct and indirect costs, market size and insurers' willingness to pay, NPS Pharmaceuticals CEO Francois Nader said. In the case of drugs to treat rare diseases, such as NPS' Gattex, NPS will give grants to rare-disease organizations that will help patients pay, and the company will offer copay assistance.

Full Story:

Related Summaries